Option Chain

Genmab ADR

GMABNASDAQ · USD

53.63USD+0.89 (+1.69%)

9610

Genmab ADR (GMAB) Option Chain

Genmab ADR trades at $53.63, up 1.69%, with an IV Rank of 19.44%. This is low versus the past year, and the company carries a market cap of $31,514M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $55.00 strike shows calls at $1.20 / $1.50 and puts at $3.00 / $3.70, both carrying about $1.67 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $55.00 calls, at 790 contracts, and the $55.00 puts, at 443, as of Nov 5, 2026.

Tracking the GMAB option chain helps you see every strike and expiry on Genmab ADR in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of GMAB options activity at a glance. Use our scanner to monitor the GMAB option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For GMAB stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where GMAB options are being actively traded, and where they are not.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
5.41	1,123	15	-0.83	8.63	7.30	8.30	45.00	-14.68	0.10	0.30	0.00	0.20	75	486	94.59
30.20	8,311	0	0.07	3.63	2.30	5.10	50.00	-5.20	0.85	1.20	0.00	1.03	33	2,507	69.80
67.89	1,475	790	1.35	0.00	1.20	1.50	55.00	+4.29	3.00	3.70	1.37	1.98	443	1,290	32.11
91.35	5,066	200	0.45	0.00	0.40	0.50	60.00	+13.77	6.90	8.00	6.37	1.08	2	343	8.65
98.57	6,985	501	0.23	0.00	0.05	0.40	65.00	+23.25	10.20	14.20	11.37	0.83	0	8	1.43

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank19.44% Low
Market cap (M$)31,514
52 weeks high-12.06%
52 weeks low123.29%
Analyst recommendationBuy
1.61
Target price$62.40
16.05% above the current stock price
Dividend—
Payout ratio0.00%
Earnings date2026-11-05
P/E41.77
Future P/E30.10
EPS (ttm)1.26
EPS growth next 5 years22.19%

As of Nov 5, 2026

Browse all Option Chain tickers